Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

2.705 -0.095 (-3.39%)
Streaming Delayed Price Updated: 12:55 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data
Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 
Via Stocktwits
Where Taysha Gene Therapies Stands With Analysts
Via Benzinga
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts
Via Benzinga
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: Taysha Gene Therapies's Earnings
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights
Via Benzinga
Earnings Scheduled For May 15, 2025
Via Benzinga
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Monday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks. 
Via MarketBeat
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024
TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.